480 related articles for article (PubMed ID: 28841909)
41. A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study).
Kataoka K; Tsushima T; Mizusawa J; Hironaka S; Tsubosa Y; Kii T; Shibuya Y; Chin K; Katayama H; Kato K; Fukuda H; Kitagawa Y;
Jpn J Clin Oncol; 2015 May; 45(5):494-8. PubMed ID: 25646357
[TBL] [Abstract][Full Text] [Related]
42. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
[TBL] [Abstract][Full Text] [Related]
43. Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
Sugase T; Sugimura K; Kanemura T; Takeoka T; Yamamoto M; Shinno N; Hara H; Omori T; Fujii Y; Mukai Y; Mikamori M; Hasegawa S; Haraguchi N; Akita H; Nishimura J; Wada H; Matsuda C; Yasui M; Miyata H
Oncology; 2022; 100(12):655-665. PubMed ID: 36198297
[TBL] [Abstract][Full Text] [Related]
44. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey.
Teker F; Yilmaz B; Kemal Y; Kut E; Yucel I
Asian Pac J Cancer Prev; 2014; 15(16):6727-32. PubMed ID: 25169516
[TBL] [Abstract][Full Text] [Related]
46. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Higuchi K; Komori S; Tanabe S; Katada C; Azuma M; Ishiyama H; Sasaki T; Ishido K; Katada N; Hayakawa K; Koizumi W;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):872-9. PubMed ID: 24867539
[TBL] [Abstract][Full Text] [Related]
47. Taxotere, cisplatin, fluorouracil, and leucovorin (TPFL)as induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Kamnerdsupaphon P; Chitapanarux I; Lorvidhaya V; Sumitsawan Y; Tharavichitkul E; Sukthomya V
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1869-73. PubMed ID: 19011334
[TBL] [Abstract][Full Text] [Related]
48. Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
El-Hadaad HA; Wahba HA; Roshdy S
J Gastrointest Cancer; 2015 Jun; 46(2):156-60. PubMed ID: 25810165
[TBL] [Abstract][Full Text] [Related]
49. Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience.
Evesque L; Benezery K; Follana P; Tuan Falk A; Doyen J; Reure J; Cavaglione G; François E
Dis Colon Rectum; 2017 Aug; 60(8):785-791. PubMed ID: 28682963
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
[TBL] [Abstract][Full Text] [Related]
51. A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study.
Céruse P; Cosmidis A; Belot A; Rabilloud M; Fuchsmann C; Poupart M; Ramade A; Tartas S; Favrel V; Pommier P; Zrounba P; Fayette J
Anticancer Drugs; 2014 Sep; 25(8):970-5. PubMed ID: 24849707
[TBL] [Abstract][Full Text] [Related]
52. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
[TBL] [Abstract][Full Text] [Related]
53. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
Yamagata Y; Saito K; Hirano K; Oya M
World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
[TBL] [Abstract][Full Text] [Related]
54. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
Yamasaki M; Miyata H; Tanaka K; Shiraishi O; Motoori M; Peng YF; Yasuda T; Yano M; Shiozaki H; Mori M; Doki Y
Oncology; 2011; 80(5-6):307-13. PubMed ID: 21778771
[TBL] [Abstract][Full Text] [Related]
55. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
[TBL] [Abstract][Full Text] [Related]
56. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
Makino T; Yamasaki M; Miyazaki Y; Wada N; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29190316
[TBL] [Abstract][Full Text] [Related]
57. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Khawandanah M; Baxley A; Pant S
J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
[TBL] [Abstract][Full Text] [Related]
58. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Haddad R; Tishler R; Wirth L; Norris CM; Goguen L; Sullivan C; O'Donnell L; Li Y; Posner M
Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):678-81. PubMed ID: 16785415
[TBL] [Abstract][Full Text] [Related]
59. FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.
Mondaca S; Chatila WK; Bates D; Hechtman JF; Cercek A; Segal NH; Stadler ZK; Varghese AM; Kundra R; Capanu M; Shia J; Schultz N; Saltz L; Yaeger R
Clin Colorectal Cancer; 2019 Mar; 18(1):e39-e52. PubMed ID: 30316684
[TBL] [Abstract][Full Text] [Related]
60. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting.
Kilickap S; Yalcin S; Ates O; Tekuzman G
Hepatogastroenterology; 2011; 58(105):208-12. PubMed ID: 21510316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
